When Should One Perform Pharmacoepidemiologic Studies?

Research output: Chapter in Book/Report/Conference proceedingChapter


The decision to conduct a pharmacoepidemiologic study can be viewed as similar to the regulatory decision about whether to approve a drug for marketing or the clinical decision about whether to prescribe a drug. In each case, decision making involves weighing the costs and risks of a therapy against its benefits. Because a central consideration is one's willingness to tolerate risk-whether from the perspectives of a manufacturer, regulator, academician, or clinician-this chapter provides also a discussion of the difference between safety and risk. It concludes with a discussion of the determinants of one's tolerance of risk.

Original languageEnglish (US)
Title of host publicationPharmacoepidemiology, Fifth Edition
Number of pages9
ISBN (Print)0470654759, 9780470654750
StatePublished - Jan 3 2012

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


  • Adverse drug reaction
  • Decision making
  • Drug regulation
  • Drug safety
  • Pharmacoepidemiologic study
  • Postmarketing study
  • Risk tolerance
  • Risk-benefit

Fingerprint Dive into the research topics of 'When Should One Perform Pharmacoepidemiologic Studies?'. Together they form a unique fingerprint.

  • Cite this

    Strom, B. L. (2012). When Should One Perform Pharmacoepidemiologic Studies? In Pharmacoepidemiology, Fifth Edition (pp. 62-70). Wiley-Blackwell. https://doi.org/10.1002/9781119959946.ch5